Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmonary Hypertension
Biotech
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off
Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study.
James Waldron
Sep 8, 2026 6:00am
Cash-strapped Quince finds salvation in reverse merger
May 18, 2026 10:32am
Bayer scraps ph.1-stage hypertension, neuropathic pain drugs
May 12, 2026 5:07am
Keros ends hypertension trial over fluid buildups around heart
Jan 15, 2025 8:25am
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Sep 10, 2024 7:57am
Gossamer touts phase 2 win but investors are wary
Dec 6, 2022 11:09am
